• Increase
  • Decrease
  • Normal

Current Size: 100%

Ed Forum 2017

2020 IWMF Global Educational Webinar with Dr. Irene Ghobrial

Sep 14, 2020
The International Waldenstrom's Macroglobulinemia Foundation invites you to join us for the third installment in our 2020 IWMF Global Educational Webinar series. Through this free interactive webinar series, you will learn from the best and brightest minds in WM research, and participate in a Q&A session from the comfort of your own home.
 
About the presentation:
This webinar will explain WM precursors - their clinical and biologic features, pathogenesis, and risk stratification - and help patients understand how clarifying the processes involved in disease progression could possibly lead to the discovery or validation of treatment targets for WM.
 
About the presenter:
Dr. Irene Ghobrial is a Professor at Dana-Farber Cancer Institute (DFCI), Harvard Medical School, Boston, MA and an Associate member of the Broad Institute, Cambridge, MA. She is the Director of the Clinical Investigator research program at Dana-Farber Cancer Institute, co-director of the Center for Prevention of Progression (CPOP) and co-leader of the Blood Cancer Research Partnership (BCRP). She is also the director of the Michele & Stephen Kirsch Laboratory. She received her medical degree from Cairo University School of Medicine, Egypt. She completed her internal medicine training at Wayne State University, MI, and her Hematology/Oncology subspecialty training at Mayo Clinic College of Medicine, MN. Her research focuses on understanding mechanisms of tumor progression from early precursor conditions such as monoclonal gammopathy of undetermined significance (MGUS) and Smoldering disease to symptomatic Multiple Myeloma (MM) and Waldenstrom Macroglobulinemia (WM). She specifically focuses on the role of the malignant bone marrow niche in regulating disease progression. She is interested in the development of new molecular/genomic markers that predict progression in precursor conditions which can identify patients who should be eligible for therapeutic interventions to prevent progression or potentially cure the disease at the early stages of the disease before clonal evolution occurs.
 
Register HERE
Section: